Lifespan vs. Healthspan - Chicago Health Magazine

LIFELONG physical activity and targeted strength training preserve joint integrity while reducing overall knee osteoarthritis risk. In young adults between 20 and 30 years of age, articular cartilage maintains peak resilience through dynamic cyclic loading. Walking for 10 minutes stimulates interstitial fluid pressurization and nutrient influx, restoring compressed tissue thickness three times faster than supine rest. However, clinicians must actively counsel young athletes on acute injury prevention. Anterior cruciate ligament ruptures peak before age 25, predisposing nearly half of affected patients to posttraumatic joint degeneration within ten years. Diagnostic vigilance must also account for normal baseline variance. A systematic review of imaging of asymptomatic knees in adults under 40 reveals cartilage defects in 11% and meniscal tears in 4%, demonstrating that incidental structural irregularities do not necessarily warrant clinical alarm.

Among cancer patients, the high financial cost of cancer care is a prevalent problem. This financial burden is also associated with potentially harmful behavioral strategies that patients might use to cope with costs, such as delaying or forgoing treatment and skipping medications. Collectively, researchers refer to this impact as financial toxicity.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.